870,000 Shares in UroGen Pharma Ltd. (NASDAQ:URGN) Acquired by Rosalind Advisors Inc.

Rosalind Advisors Inc. acquired a new stake in UroGen Pharma Ltd. (NASDAQ:URGN) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 870,000 shares of the company’s stock, valued at approximately $9,266,000. UroGen Pharma makes up about 4.6% of Rosalind Advisors Inc.’s holdings, making the stock its 8th biggest position.

Several other large investors have also recently added to or reduced their stakes in the company. BNP Paribas Financial Markets boosted its position in shares of UroGen Pharma by 221.8% in the third quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company’s stock valued at $109,000 after acquiring an additional 5,890 shares during the period. Oppenheimer & Co. Inc. acquired a new stake in UroGen Pharma in the 4th quarter worth about $126,000. Intech Investment Management LLC bought a new stake in UroGen Pharma in the 3rd quarter valued at about $155,000. Verition Fund Management LLC acquired a new position in shares of UroGen Pharma during the 3rd quarter worth approximately $168,000. Finally, GSA Capital Partners LLP bought a new position in shares of UroGen Pharma during the third quarter worth approximately $249,000. Institutional investors own 91.29% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on URGN. LADENBURG THALM/SH SH started coverage on UroGen Pharma in a research note on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price target for the company. HC Wainwright cut their target price on UroGen Pharma from $64.00 to $55.00 and set a “buy” rating for the company in a research report on Tuesday, March 11th. Finally, D. Boral Capital reissued a “buy” rating and set a $25.00 target price on shares of UroGen Pharma in a report on Monday, March 10th. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, UroGen Pharma has a consensus rating of “Buy” and an average target price of $38.20.

Insiders Place Their Bets

In other news, General Counsel Jason Drew Smith sold 7,379 shares of the company’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total value of $82,202.06. Following the completion of the transaction, the general counsel now owns 26,468 shares of the company’s stock, valued at $294,853.52. This represents a 21.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Mark Schoenberg sold 4,551 shares of the firm’s stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $11.14, for a total transaction of $50,698.14. Following the completion of the transaction, the insider now owns 145,666 shares of the company’s stock, valued at approximately $1,622,719.24. This trade represents a 3.03 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.10% of the company’s stock.

UroGen Pharma Trading Up 0.9 %

Shares of UroGen Pharma stock opened at $12.13 on Friday. The firm’s 50 day moving average is $10.54 and its 200 day moving average is $11.59. The firm has a market capitalization of $559.12 million, a PE ratio of -3.85 and a beta of 1.12. UroGen Pharma Ltd. has a 1 year low of $9.03 and a 1 year high of $20.70. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The firm had revenue of $24.57 million for the quarter, compared to the consensus estimate of $25.25 million. Equities research analysts forecast that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.